Background: The objective of this study was to explore the effects of viral co-detection in individuals recently vaccinated with the live-attenuated intranasal influenza virus vaccine (LAIV) on the detection of influenza RNA.
Introduction
Influenza is the most common respiratory viral infection for which there is a vaccine. Seasonal vaccination is of special importance to individuals at high risk of morbidity resulting from influenza infection. Many acute pulmonary exacerbations in children with cystic fibrosis (CF) are associated with respiratory virus infections. 1 Flumist Ò , a live-attenuated influenza virus vaccine (LAIV) administered by intranasal spray, was approved for seasonal use in Canadians 2-59 y of age in June 2010. LAIV was subsequently introduced into publicly funded Canadian vaccination programs in the 2012-2013 influenza season. In Canada, LAIV is currently recommended for use in children and adolescents 2-17 y old, including non-immunosuppressed individuals with chronic conditions (including CF) with no contraindications to LAIV. 2 Recently, the U.S. Advisory Committee on Immunization voted against the use of LAIV for the 2016-17 influenza season, given its poor or relatively lower effectiveness when compared with the injectable vaccine from 2013 to 2016. 3 Viral interference is a phenomenon whereby infection with one virus limits infection and replication of a second virus. 4 Previous studies introduced the concept of viral interference between live vaccines [5] [6] [7] [8] [9] [10] [11] [12] and form the basis for the current vaccine recommendations, which advise to either administer live vaccines in the same bodily compartment concurrently or at an interval of 4 weeks. 13 The U.S. Advisory Committee on Immunization Practices recommends administering LAIV in the same way as other live vaccines are administered, 14 while the Canadian National Advisory Committee on Immunizations does not impose any specific interval between LAIV and other live-attenuated vaccines, as long as these are administered in different body compartments. According to the interference concept, LAIV replication in recent vaccinees could be impaired by interferon produced from a previously administered live vaccine or from naturally acquired non-influenza respiratory virus (NIRVs) infections. As replication of LAIV vaccine strains in the nasal mucosa is the first step required to induce protection, this interference may potentially impact LAIV effectiveness. This study represents the first step in evaluating this potential association.
CF is characterized by, among other things, abnormal inflammatory responses to viral respiratory infections, 15 16 and chronic inflammation of the lungs and airways. 17 Both of these characteristics can impact the incidence and course of viral infections, making this patient population of particular interest when evaluating viral interference. The objective of this study was thus to explore the effects of viral co-detection (i.e. a preexisting NIRV infection) on the detection of influenza RNA after vaccination with LAIV in children and adolescents with CF and their healthy siblings.
Results
A total of 76 subjects (59 with CF) attending the 2 participating CF clinics were enrolled and vaccinated with LAIV between October 8-November 28, 2013 ( Table 1 ). The mean age of the cohort was 10.2 y (SD D 4.98, range: 2-19 years), about half the participants were female (39/76) and 95% (72/76) of the cohort was vaccinated against influenza in the year before study participation: 29 of 72 previously vaccinated (40%) had received LAIV and the remainder had received the trivalentinactivated vaccine. One participant was lost to follow-up (after D0) and the D0-sample was missing for another participant. A total of 372 nasal swabs were received. Compliance with the protocol for obtaining nasal swabs from participants was high: of the self-procured samples, only 0.7% (2/304) did not have any detectable levels of influenza RNA and RNP (1 sample each on D1 and D7) and were considered missing. A very low amount of human DNA (Ct RNP >37) was found in only 1 of 372 samples. Overall, 69% (52/75) of the study cohort had PCR-detected influenza RNA (either type A and/or B) during follow-up (D1-D7). Specifically, 24 subjects had RT-PCR detected influenza B virus RNA only, 7 had influenza A virus RNA detected only and 21 subjects had both virus types detected at least once throughout follow up. Detailed results of the detection of influenza viruses are published elsewhere. 18 Results were not stratified by influenza type given the small number of subjects.
Genetic material from at least one NIRV was identified in 22 subjects on D0, and none of the viruses detected on D0 were influenza types A or B. At baseline, 3 healthy participants were infected with enterovirus-rhinovirus and one with human coronavirus 1. No healthy participants were found to be infected with 2 with NIRVs (referred to as co-infection) at baseline. Among participant with CF, 14 were found to be infected with enterovirus-rhinovirus, one with parainfluenza virus 1, one with parainfluenza virus 2, one co-infected with human coronavirus OC43 and enterovirus-rhinovirus and one co-infected with parainfluenza 4 and enterovirus-rhinovirus. The prevalence of detected NIRV on D0 was greater in subjects with CF compared with healthy subjects, although wide credible intervals preclude definitive conclusions (18/58 vs. 4/17, respectively; prevalence ratio: 1.52, 95% CrI: 0.58, 3.81).
Overall, fewer participants had detectable influenza RNA during follow-up in the group that had a NIRV infection detected at baseline compared with those that did not have an NIRV at baseline, however this difference was not statistically significant (59% vs. 75%; RD D 16% 95% CrI: ¡7, 39%). This was also observed in participants with CF alone (66% vs. 74%; RD D 8% 95% CrI: ¡16, 33%) and in healthy participants only (75% vs. 30%; RD D 45%, 95% CrI: ¡2, 81%). The effect estimate for the entire cohort was likely unbiased by diagnostic measurement error from the 2 viral detection assays used (Fig. 1) . Rather, the estimated RD shifted slightly away from the null and the variability in the 95% CrI increased in both sensitivity analyses.
An episode of virus detection is defined as a stretch of consecutive samples positive for influenza virus genetic material. Among LAIV vaccinees in whom influenza RNA (either type A and/or type B) was detected throughout follow-up, 14 episodes of influenza virus detection occurred in the 13 D0-NIRV-positive subjects (total of 52 d of follow-up) compared with 44 episodes in the 39 D0-NIRV-negative subjects (total of 153 d of follow-up). This corresponds to 0.27 detection episodes/day in the NIRV-positive group (95% CI: 0.15, 0.43) versus 0.29 detection episodes/day in the NIRV-negative group (95% CI: 0.21, Furthermore, peak detection of influenza RNA in subjects that tested positive for a NIRV on D0 occurred later (peak at D4) than non-NIRV-infected subjects (peak at D1), regardless of CF status (Fig. 2) . Detection appeared to decrease by D7 in all except healthy participants without an NIRV. This opposite trend observed likely relates to the increased variation due to the small number of D0-NIRV negative participants without CF. The mean duration of detection of RT-PCR-detected influenza RNA in the entire cohort was 2.09 d (95% CrI: 1.73, 2.48). The D0-NIRV-positive subjects had influenza RNA detected for 0.49 d more compared with NIRV-negative subjects, but wide credible intervals preclude definitive conclusions (95% CrI: ¡0.37, 1.26) ( Table 2) .
The study had too small a sample size to accurately estimate the effects of both NIRV co-detection and CF status on the detection of influenza virus RNA post-LAIV vaccination (see Details & Results of Univariable and Multivariable Logistic Regression Models, see Appendix B Section 1, Supplemental Material).
Discussion
Overall, the prevalence of detected NIRV on D0 was greater (albeit statistically non-significantly) in subjects with CF compared with their healthy sibling participant counterparts. Some published evidence does not support the theory that pediatric patients with CF experience an increased incidence of laboratory-confirmed respiratory viral infections compared with healthy subjects, [19] [20] [21] while one recent study supports this theory. 22 Rather, it has been postulated that the increased prevalence of viral respiratory infections may be attributed to differences in the duration of infections (and the consequent duration of viral nucleic acid detection) due to a diminished specific antiviral defense [22] [23] [24] in patients with CF. 25 Furthermore, our 2 sensitivity analyses indicated that the RD estimate was robust to potential information bias from the diagnostic assays used to detect the presence of respiratory viruses. The increased variability in the sensitivity analyses did, however, highlight the need for adequate sample size to account for this potential measurement error when making inferences using these diagnostic assays.
We also determined that a slightly larger proportion of D0-NIRV negative participants had influenza RNA detected following vaccination compared with those who were positive for NIRV. This moderate trend was also observed when the duration of the detection episodes was compared between both groups. No D0-NIRV positive subjects were symptomatic (chest congestion, coughing, difficulty breathing, wheezing and/or increased sputum) at baseline. Since detection of NIRV genetic material on D0 may represent a carryover from a recent previous infection, the differences in the detection of influenza virus post-LAIV administration in those with and without a NIRV infection could be related to the primary respiratory virus infection. This phenomenon, described as viral interference, occurs when infection with one virus limits infection and replication of a second virus. 4 Mechanisms postulated to contribute to viral interference include competition for cellular receptors, competition for molecular substrates required for replication and induction of inhibitory host proteins, such as interferon, for the initiation of an anti-viral response. 26, 27 In this way, individuals currently or recently infected with a respiratory virus on D0 could have less replication of the LAIV strains and thus less influenza RNA detected during follow-up. These findings support the results from a 2012 study which determined that viral detection was significantly shorter in patients who were co-infected by pH1N1 and NIRV or by 2 different NIRVs compared with those who were infected with only one virus (regardless of what virus was detected). 28 Furthermore, a large degree of bias in the overall RD estimate was not observed when potential misclassification of D0-NIRV status and influenza detection status during follow-up was taken into account This is not unexpected for 2 reasons. First, a large error rate was assumed from the literature for only the sensitivity of the diagnostic assay used to ascertain exposure (xTAG Ò ). Second, the error rates for D0-NIRV infection and influenza RNA detection were assumed to be non-differential (independent).
The results of this study should be interpreted in light of several limitations. First, the RT-PCR primers used to identify influenza RNA were not specific to cold-adapted (LAIV) influenza viruses. It is therefore possible that the influenza viruses detected were naturally circulating, and not vaccine-strain. However, specimen collection occurred before the beginning of the seasonal epidemic in 2013, minimizing the possibility that the specimens collected were not LAIV. Similarly, as the virus detected on the nasal swabs was not cultured, the identity of the RT-PCR signal as live viruses cannot be definitively be confirmed. Second, we also found a larger number of influenza detection episodes than subjects, indicating the detection of influenza RNA on non-consecutive days during follow-up for 6 subjects. These biologically implausible results are likely due to sub-optimal swabbing during specimen collection or to the thawing of samples during transport. This could also mean that the viral concentration may have been below the RT-PCR assay's limit of detection. Third, some studies that evaluated the duration of viral detection of pandemic influenza [29] [30] [31] required at least 2 consecutive negative specimens to infer the end of detection and avoid under-estimating the detection duration. We decided to not censor detection in this manner given that the study samples were not procured on consecutive days following vaccination, the one-week follow-up was of relatively short duration and non-consecutive detection was found for a small subset of the study population (8%). Fourth, the small sample size of our study should be emphasized, as the results obtained in this analysis may be due to chance alone. As highlighted by our sensitivity analyses, further research is required to explore and potentially confirm our findings. Fifth, we did not have information linking siblings in this data set and were thus unable to explore the effect of co-habitation of CF and non-CF siblings on D0-NIRV status. Finally, we were unable to evaluate whether influenza virus RNA detection differs between clinically apparent and asymptomatic D0-NIRVpositive subjects given that only one subject (D0-NIRV negative) was mildly symptomatic on the day of vaccination (coughing) and the estimation of D0-NIRV viral load was not possible. Similarly, changes in longer-term detection of influenza could not be evaluated given that follow-up was only for one week following vaccination. However, we believe this duration of follow-up is adequate since previous pediatric studies showed that influenza virus shedding post-LAIV was highest within this time period. [32] [33] [34] To our knowledge this is the first study conducted evaluating viral interference, a controversial and understudied topic in the realm of live-attenuated vaccines, in a pediatric cohort with CF. Given the potential signal for viral interference observed in this study cohort, results of this study also raise the question of whether LAIV's efficacy and effectiveness could be affected by a contemporary viral infection at the time of vaccination with LAIV. 35 As this study does not evaluate any of these outcomes, future research should first further assess the signal for viral interference with CF and, contingent on those results, then evaluate potential changes in vaccine efficacy associated with the presence of respiratory virus infection at the time of LAIV administration. While previous studies have evaluated the effect of viral interference between LAIV-strain viruses, 27 our research is also the first to evaluate the effect of a natural respiratory virus infection, at the time of LAIV-vaccination, on the detection of influenza in recent pediatric LAIV vaccinees. Given that viral replication is required to elicit protection by LAIV 27 and that viral interference may prevent LAIV-replication, further studies are required to determine the clinical significance of these findings.
Methods

Study population
Individuals 2 to 19 y of age with CF that had no contraindication to LAIV 18 were recruited for a prospective cohort study. Subjects were followed in either one of 2 participating CF clinics in Canada (British Columbia Children's Hospital, Vancouver and The Montreal Children's Hospital, Montreal). Participants' siblings were also recruited if they had no chronic health conditions, respiratory or other (hereby referred to as 'healthy'). The informed consent for this study did not include a clause allowing for vaccination of contra-indicated children.
Vaccination & follow-up
After obtaining informed consent, participants were vaccinated as part of their regular process of care between October 8 and November 28, 2013, before the influenza season began. LAIV was administered to participants as a 0. 36 Participants were followed for 8 d (day of vaccination plus 7 days) since previous pediatric studies showed that influenza virus shedding post-LAIV was highest within this time period. [32] [33] [34] Trained research nurses took flocked nasal swabs (Copan Diagnostics, Murrieta, CA, USA) from participants immediately before vaccination on day 0 (D0). Self-procured swabs (by participants and/or their parents, trained by research nurses) were obtained on days 1, 2, 4 and 7 (D1-D7, respectively) following vaccination. Swabs were placed in 2.0 mL of universal transport medium (Copan) after specimen procurement and then kept in home freezers and delivered frozen to the hospital sites. At the study sites, the specimens were stored at ¡808C. At the end of the study, all diagnostic testing for respiratory viruses was performed at the Laboratoire de Sant e Publique du Qu ebec.
Laboratory methods
Nucleic acids from D0 samples were extracted using the NucliSENS easyMag platform (bioM erieux, St. Laurent, Canada) according to the manufacturer's instructions and tested for the presence of NIRV genetic material with the xTAG Ò Respiratory Virus Panel FAST V2 (Luminex Corporation, Toronto, Canada) multiplex RT-PCR assay (Luminex Molecular Diagnostics Inc., Toronto, ON, Canada). 37 Specifically, the study samples were tested for the presence of 
Statistical analyses
Descriptive statistics and graphics were created using Stata 13.1. In addition, Bayesian methods were used to derive inferences for between-group comparisons. The proportions of interest as well as their 95% credible intervals (CrI) and that of the risk difference (RD) were estimated using the Gibbs sampler as implemented by WinBUGS (Version 1.4.3, MRC Biostatistics Unit, Cambridge, UK). Differences among the proportions of NIRV-positive and -negative groups were summarized from the posterior distribution, estimated using the binomial likelihood and Jeffreys prior (b (0.5,0.5)). Similarly, differences in influenza detection rates between NIRV-positive and -negative groups were summarized from the posterior distribution, estimated using a Poisson likelihood and a noninformative prior distribution (gamma(0.001,0.001)) on the Poisson parameter. Univariable and multivariable logistic regression models (with non-informative normal prior distributions on the intercepts and slopes) were used to further estimate the effect of NIRVstatus at baseline on the detection of influenza RNA (yes/no) throughout follow-up. The missing outcome variable for one participant and the missing NIRV-status for another participant was multiply imputed (see Details & Results of Univariable and Multivariable Logistic Regression Models, Appendix B Section 1, Supplemental Material).
Sensitivity analysis: Measurement error
Both the xTAG Ò assay used for the identification of a D0-NIRV (exposure) and RT-PCR assays used for the detection of influenza RNA (outcome) are subject to a degree of inaccuracy. Consequently, misclassification of D0-NIRV infections and of influenza RNA detection during follow-up may bias the estimated RD. However, most analyses do not account for this potential bias and erroneously assume 100% sensitivity and 100% specificity for these diagnostic tests. We conducted 2 sensitivity analyses whereby we accounted for errors in the diagnostic tests by assigning informative prior distributions to the sensitivities and specificities of both assays (see Sensitivity Analysis Methodology, Appendix B Section 2, Supplemental Material). The first sensitivity analysis assumed perfect specificity (no false positive results) for both assays while in the second sensitivity analysis this assumption was relaxed.
Abbreviations
CF
Cystic Fibrosis Ct threshold cycle LAIV Live attenuated influenza virus vaccine NIRV non-influenza respiratory virus RD risk difference RNP RNase P RT-PCR Reverse transcription polymerase chain reaction
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